CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma
Biomolecules and Biomedicine · 2024
DOI: 10.17305/bb.2024.10397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2024. Verfasst von Rumeng Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Melanoma, Colonic Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Anhui Province.
Abstract (Originalsprache)
Colon cancer, thyroid cancer, and melanoma are common malignant tumors that seriously threaten human health globally. The B-Raf proto-oncogene, serine/threonine kinase (BRAF)(V600E) mutation is an important driver gene mutation in these cancer types. In this study, we identified that collagen triple helix repeat containing 1 (CTHRC1) expression was associated with the BRAF(V600E) mutation in colon cancer, thyroid cancer, and melanoma. Based on database analysis and clinical tissue studies, CTHRC1 was verified to correlate with poor prognosis and worse clinicopathological features in colon cancer and thyroid cancer patients, but not in patients with melanoma. Several signaling pathways, immune cell infiltration, and immunotherapy markers were associated with CTHRC1 expression. Additionally, a high level of CTHRC1 was correlated with decreased sensitivity to antitumor drugs (vemurafenib, PLX-4720, dabrafenib, and SB-590885) targeting the BRAF(V600E) mutation. This study provides evidence of a significant correlation between CTHRC1 and the BRAF(V600E) mutation, suggesting its potential utility as a diagnostic and prognostic biomarker in human colon cancer, thyroid cancer, and melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
- Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
- Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
- Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China; Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province
Zitieren
APA
Zhang, R., Wang, Z., Wang, H., Li, L., Dong, L., Ding, L., Li, Q., Zhu, L., Zhang, T., Zhu, Y., & Ding, K. (2024). CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2024.10397
Vancouver
Zhang R, Wang Z, Wang H, Li L, Dong L, Ding L, et al. CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma. Biomolecules and Biomedicine. 2024. doi:10.17305/bb.2024.10397
BibTeX
@article{Zhang2024,
author = {Zhang, Rumeng and Wang, Zhihao and Wang, Huan and Li, Lin and Dong, Lin and Ding, Lin and Li, Qiushuang and Zhu, Linyan and Zhang, Tiantian and Zhu, Yong and Ding, Keshuo},
title = {CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma},
journal = {Biomolecules and Biomedicine},
year = {2024},
doi = {10.17305/bb.2024.10397}
}
EUVIMED